AAAAAA

   
Results: 1-8 |
Results: 8
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373
Authors: Gulick, RM Smeaton, LM D'Aquila, RT Eron, JJ Currier, JS Gerber, JG Acosta, E Sommadossi, JP Tung, R Snyder, S Kuritzkes, DR Murphy, RL
Citation: Rm. Gulick et al., Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373, J INFEC DIS, 183(5), 2001, pp. 715-721
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884
Authors: Fletcher, CV Acosta, EP Cheng, HL Haubrich, R Fischl, M Raasch, R Mills, C Hu, XJ Katzenstein, D Remmel, RP Gulick, RM
Citation: Cv. Fletcher et al., Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884, AIDS, 14(16), 2000, pp. 2495-2501
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359
Authors: Gulick, RM Hu, XJ Fiscus, SA Fletcher, CV Haubrich, R Cheng, HL Acosta, E Lagakos, SW Swanstrom, R Freimuth, W Snyder, S Mills, C Fischl, M Pettinelli, C Katzenstein, D
Citation: Rm. Gulick et al., Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359, J INFEC DIS, 182(5), 2000, pp. 1375-1384
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
Authors: Eron, JJ Smeaton, LM Fiscus, SA Gulick, RM Currier, JS Lennox, JL D'Aquila, RT Rogers, MD Tung, R Murphy, RL
Citation: Jj. Eron et al., The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850), J INFEC DIS, 181(5), 2000, pp. 1622-1628
Assessing the benefits of antiretroviral therapy
Authors: Gulick, RM
Citation: Rm. Gulick, Assessing the benefits of antiretroviral therapy, ANN INT MED, 133(6), 2000, pp. 471-473
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
Authors: Gulick, RM Mellors, JW Havlir, D Eron, JJ Meibohm, A Condra, JH Valentine, FT McMahon, D Gonzalez, C Jonas, L Emini, EA Chodakewitz, JA Isaacs, R Richman, DD
Citation: Rm. Gulick et al., 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine, ANN INT MED, 133(1), 2000, pp. 35-39
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
Authors: Murphy, RL Gulick, RM DeGruttola, V D'Aquila, RT Eron, JJ Sommadossi, JP Currier, JS Smeaton, L Frank, I Caliendo, AM Gerber, JG Tung, R Kuritzkes, DR
Citation: Rl. Murphy et al., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection, J INFEC DIS, 179(4), 1999, pp. 808-816
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults - AIDS clinical trials group protocols 150 and 258
Authors: Gulick, RM McAuliffe, V Holden-Wiltse, J Crumpacker, C Liebes, L Stein, DS Meehan, P Hussey, S Forcht, J Valentine, FT
Citation: Rm. Gulick et al., Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults - AIDS clinical trials group protocols 150 and 258, ANN INT MED, 130(6), 1999, pp. 510-514
Risultati: 1-8 |